Post-Authorization Safety Study of OZURDEX® (Dexamethasone Intravitreal Implant): A Prospective Observational Study to Evaluate Long-Term Safety in Real-World Clinical Practice (CONSTANCE)

First published: 13/09/2016 Last updated: 14/03/2024



# Administrative details

## **EU PAS number**

EUPAS15160

#### **Study ID**

34210


#### **DARWIN EU® study**

No

#### **Study countries**

France

Germany



## **Study description**

This is a multi-center, prospective, observational study to evaluate the longterm safety profile of OZURDEX® in adult patients diagnosed with macular oedema following CRVO or BRVO or patients with non-infectious posterior segment uveitis, under conditions of routine medical practice in accordance with the product's Summary of Product Characteristics. The study will target recruitment of 650 patients, 500 with RVO and 150 with non-infectious posterior segment uveitis, with patients receiving >2 implants constituting at least 40%  $(N \ge 260)$  of the study sample. As an observational study, all treatment decisions are at the discretion of the patient's health care provider and are not defined or mandated by the study design or protocol. Patients will receive OZURDEX® under routine clinical practice, and if they elect to participate in the study (i.e. provide informed consent), they will be followed for two years from study enrollment. The research objectives of this study are as follows: Primary objective: To evaluate the long-term safety of OZURDEX®, including the identified and potential risks as listed in the risk management plan, in patients with macular oedema following RVO or non-infectious posterior segment uveitis who are treated with OZURDEX® under conditions of routine medical practice. Secondary objective: To describe treatment patterns for patients receiving OZURDEX® for the treatment of macular oedema following RVO or noninfectious posterior segment uveitis in real-world clinical practice.

#### **Study status**

Finalised

# Research institutions and networks

# Institutions

# Real World & Late Phase Research (RWLPR), Quintiles

France

First published: 20/03/2015

Last updated: 20/08/2024

Institution Other

Multiple centres: 75 centres are involved in the study

# Contact details

## Study institution contact

Catherine Godefroy CT.Disclosures@abbvie.com

Study contact

CT.Disclosures@abbvie.com

Primary lead investigator Catherine Godefroy

Primary lead investigator

# Study timelines

Date when funding contract was signed Planned: 01/01/2011 Actual: 01/01/2011

**Study start date** Planned: 29/03/2012 Actual: 29/03/2012

**Date of final study report** Planned: 22/09/2016 Actual: 30/09/2016

# Sources of funding

• Pharmaceutical company and other private sector

## More details on funding

Allergan

# Study protocol

Allergan\_Ozurdex\_PASS\_protocol\_17Jan2012\_v1.6\_Final\_signed\_Redacted.pdf (256.12 KB)

# Regulatory

## Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

# Other study registration identification numbers and links

206207-025

# Methodological aspects

Study type

# Study type list

## **Study topic:**

Disease /health condition Human medicinal product

## Study type:

Non-interventional study

## Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

## Data collection methods:

Primary data collection

## Main study objective:

To evaluate the long-term safety of OZURDEX®, including theidentified and potential risks as listed in the risk management plan, in patients withmacular oedema following RVO or non-infectious posterior segment uveitis who aretreated with OZURDEX® under conditions of routine medical practice.

# Study Design

Non-interventional study design Cohort Other

Non-interventional study design, other Post-Authorization Safety Study, Prospective, observational study

# Study drug and medical condition

## Anatomical Therapeutic Chemical (ATC) code

(S01BA01) dexamethasone dexamethasone

## Additional medical condition(s)

Macular Oedema secondary to Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO) and inflammation of the posterior segment of the eye presenting as non-infectious uveitis (non-infectious posterior segment uveitis)

# Population studied

## Short description of the study population

Patients who are treated with OZURDEX for macular oedema following Branch retinal vein occlusion (BRVO) or Central retinal vein occlusion (CRVO), or noninfectious posterior segment uveitis, under conditions of routine medical practice in accordance with the SmPC.

Inclusion Criteria:

1. Age  $\geq$  18 years

2. Physician diagnosis of macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) or non-infectious posterior segment uveitis.

3. Treatment with OZURDEX (either initial or repeat)

4. Patients treated with OZURDEX in a completed clinical trial were eligible5. Patient or legal representative provides informed consent according to local

regulations

## Age groups

Adults (18 to < 46 years) Adults (46 to < 65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

## Special population of interest

Other

## Special population of interest, other

Macular oedema patients

## **Estimated number of subjects**

650

# Study design details

## Outcomes

To evaluate the long-term safety of OZURDEX®, including the identified and potential risks as listed in the risk management plan, in patients with macular oedema following RVO or non-infectious posterior segment uveitis who are treated with OZURDEX® under conditions of routine medical practice.

## Data analysis plan

All SAEs and ADRs of special interest will be recorded and coded using MedDRA terms and presented by SOC, HLT, and PT. The demographic and clinical profile of the study population will be described using baseline data. All analyses will be stratified by indication and by new initiators of OZURDEX versus previously treated with OZURDEX. Frequency of SAEs and ADRs of special interest will be calculated as the number of patients who have a specific event starting during the study period, divided by the number of patients enrolled, multiplied by 100. Incidence rates of SAEs and ADRs of special interest will be estimated by dividing the number of incident cases by the person-time at risk and as annualized rates. Time at risk will be defined as the time between dates of first injection of OZURDEX to end of follow-up (completion of follow-up / study discontinuation). Case narratives will be provided for each SAE and ADRs of special interest.

## Documents

#### **Study results**

Allergan\_Ozurdex\_PASS\_Abstract\_Redacted.pdf(682.66 KB)

## Data management

## Data sources (types)

Other

## Data sources (types), other

Prospective patient-based data collection

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

## **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**

No